SI-BONE, Inc. reported $214M of revenue over the trailing twelve months, +15% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $214M (to Q2 2026). Net income: −$15M, trailing twelve months to Q2 2026. Free cash flow: −$4.4M, trailing twelve months to Q2 2026. Operating margin: −8.4%, trailing twelve months to Q2 2026.

SIBNSI-BONE, Inc.

Healthcare

$18.85+23% 1Y

$18.85

$11.6152 weeks$21.40

SIBN as reported

SI-BONE, Inc. reported $214M of revenue over the trailing twelve months, +15% on the year before. 10 reported series are charted on this page, each one as filed.

$214M

Revenue, trailing twelve months · to Q2 2026 · +15% against the twelve months before

Net income: −$15M
Net income · −38% year on year · trailing twelve months to Q2 2026
Free cash flow: −$4.4M
Free cash flow · −66% year on year · trailing twelve months to Q2 2026
Operating margin: −8.4%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SIBN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$214M	+15%	Q2 2026
Net income	−$15M	−38%	Q2 2026
EPS	−$0.34	−39%	Q2 2026
Gross margin	80%	n/a	Q2 2026
Operating margin	−8.4%	n/a	Q2 2026
Net margin	−7.0%	n/a	Q2 2026
ROE	−10%	n/a	Q2 2026
ROA	−7.5%	n/a	Q2 2026
ROIC	−9.4%	n/a	Q2 2026
Free cash flow	−$4.4M	−66%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.